S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
Log in
NASDAQ:PTE

PolarityTE Competitors

$1.28
-0.01 (-0.78 %)
(As of 03/8/2021 02:32 PM ET)
Add
Compare
Today's Range
$1.25
Now: $1.28
$1.35
50-Day Range
$0.92
MA: $1.28
$1.78
52-Week Range
$0.55
Now: $1.28
$2.38
Volume53,849 shs
Average Volume11.65 million shs
Market Capitalization$76.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29

Competitors

PolarityTE (NASDAQ:PTE) Vs. SURF, CMPI, EIGR, PDLI, CASI, and CABA

Should you be buying PTE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to PolarityTE, including Surface Oncology (SURF), Checkmate Pharmaceuticals (CMPI), Eiger BioPharmaceuticals (EIGR), PDL BioPharma (PDLI), CASI Pharmaceuticals (CASI), and Cabaletta Bio (CABA).

Surface Oncology (NASDAQ:SURF) and PolarityTE (NASDAQ:PTE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Surface Oncology and PolarityTE, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surface Oncology02202.50
PolarityTE02202.50

Surface Oncology currently has a consensus target price of $12.00, indicating a potential upside of 61.29%. PolarityTE has a consensus target price of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, analysts clearly believe PolarityTE is more favorable than Surface Oncology.

Institutional and Insider Ownership

52.0% of Surface Oncology shares are owned by institutional investors. Comparatively, 16.5% of PolarityTE shares are owned by institutional investors. 35.0% of Surface Oncology shares are owned by insiders. Comparatively, 5.5% of PolarityTE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Surface Oncology has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, PolarityTE has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Valuation and Earnings

This table compares Surface Oncology and PolarityTE's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surface Oncology$15.36 million19.86$-54,790,000.00($1.97)-3.81
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35

Surface Oncology has higher revenue and earnings than PolarityTE. Surface Oncology is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surface Oncology and PolarityTE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surface OncologyN/A-29.77%-17.05%
PolarityTE-674.12%-169.92%-105.62%

Summary

Surface Oncology beats PolarityTE on 10 of the 12 factors compared between the two stocks.

Checkmate Pharmaceuticals (NASDAQ:CMPI) and PolarityTE (NASDAQ:PTE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Checkmate Pharmaceuticals and PolarityTE, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkmate Pharmaceuticals01302.75
PolarityTE02202.50

PolarityTE has a consensus target price of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, analysts plainly believe PolarityTE is more favorable than Checkmate Pharmaceuticals.

Valuation & Earnings

This table compares Checkmate Pharmaceuticals and PolarityTE's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkmate PharmaceuticalsN/AN/A$-28,290,000.00N/AN/A
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35

Checkmate Pharmaceuticals has higher earnings, but lower revenue than PolarityTE.

Institutional & Insider Ownership

75.6% of Checkmate Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of PolarityTE shares are held by institutional investors. 5.5% of PolarityTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Checkmate Pharmaceuticals and PolarityTE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkmate PharmaceuticalsN/AN/A-57.12%
PolarityTE-674.12%-169.92%-105.62%

Summary

Checkmate Pharmaceuticals beats PolarityTE on 7 of the 10 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 68.8% of Eiger BioPharmaceuticals shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 5.8% of Eiger BioPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares PolarityTE and Eiger BioPharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35
Eiger BioPharmaceuticalsN/AN/A$-70,250,000.00($3.08)-2.93

Eiger BioPharmaceuticals has lower revenue, but higher earnings than PolarityTE. Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for PolarityTE and Eiger BioPharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PolarityTE02202.50
Eiger BioPharmaceuticals00203.00

PolarityTE currently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Eiger BioPharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 176.85%. Given PolarityTE's higher possible upside, equities analysts clearly believe PolarityTE is more favorable than Eiger BioPharmaceuticals.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and Eiger BioPharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PolarityTE-674.12%-169.92%-105.62%
Eiger BioPharmaceuticalsN/A-100.60%-57.76%

Summary

Eiger BioPharmaceuticals beats PolarityTE on 9 of the 12 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and PDL BioPharma (NASDAQ:PDLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 86.2% of PDL BioPharma shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 2.2% of PDL BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares PolarityTE and PDL BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82

PDL BioPharma has higher revenue and earnings than PolarityTE. PolarityTE is trading at a lower price-to-earnings ratio than PDL BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and PDL BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PolarityTE02202.50
PDL BioPharma0000N/A

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than PDL BioPharma.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, PDL BioPharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and PDL BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PolarityTE-674.12%-169.92%-105.62%
PDL BioPharmaN/A-10.04%-8.29%

Summary

PDL BioPharma beats PolarityTE on 7 of the 13 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares PolarityTE and CASI Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35
CASI Pharmaceuticals$4.13 million68.42$-46,030,000.00($0.42)-5.43

CASI Pharmaceuticals has lower revenue, but higher earnings than PolarityTE. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and CASI Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PolarityTE02202.50
CASI Pharmaceuticals00203.00

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 87.22%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than CASI Pharmaceuticals.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Profitability

This table compares PolarityTE and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PolarityTE-674.12%-169.92%-105.62%
CASI Pharmaceuticals-402.87%-60.96%-42.48%

Summary

CASI Pharmaceuticals beats PolarityTE on 9 of the 13 factors compared between the two stocks.

PolarityTE (NASDAQ:PTE) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Valuation & Earnings

This table compares PolarityTE and Cabaletta Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolarityTE$5.65 million13.62$-92,490,000.00($3.70)-0.35
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.76

Cabaletta Bio has lower revenue, but higher earnings than PolarityTE. Cabaletta Bio is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

16.5% of PolarityTE shares are held by institutional investors. Comparatively, 68.0% of Cabaletta Bio shares are held by institutional investors. 5.5% of PolarityTE shares are held by company insiders. Comparatively, 6.5% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for PolarityTE and Cabaletta Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PolarityTE02202.50
Cabaletta Bio00303.00

PolarityTE presently has a consensus price target of $4.00, indicating a potential upside of 214.96%. Cabaletta Bio has a consensus price target of $20.3333, indicating a potential upside of 80.26%. Given PolarityTE's higher possible upside, research analysts clearly believe PolarityTE is more favorable than Cabaletta Bio.

Risk & Volatility

PolarityTE has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Profitability

This table compares PolarityTE and Cabaletta Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PolarityTE-674.12%-169.92%-105.62%
Cabaletta BioN/A-22.99%-22.38%

Summary

Cabaletta Bio beats PolarityTE on 9 of the 13 factors compared between the two stocks.


PolarityTE Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Surface Oncology logo
SURF
Surface Oncology
1.3$7.50-0.0%$305.08 million$15.36 million-11.36Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$14.14-3.0%$295.46 millionN/A0.00Upcoming Earnings
Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.03-0.6%$295.39 millionN/A-3.72Upcoming Earnings
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.28-0.4%$281.35 million$4.13 million-5.07Upcoming Earnings
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$11.22-3.7%$259.79 millionN/A-8.19Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.87-2.9%$242.85 millionN/A-4.92Upcoming Earnings
Gap Down
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.9%$208.23 million$104.39 million-3.40
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.75-2.7%$208.17 million$2.45 million-2.23Analyst Report
Axcella Health logo
AXLA
Axcella Health
1.6$5.28-1.5%$201.22 millionN/A-2.46
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.20-1.2%$201.03 millionN/A-5.73Upcoming Earnings
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.08-0.5%$197.61 million$29.35 million-2.42Upcoming Earnings
INmune Bio logo
INMB
INmune Bio
1.5$13.71-4.4%$192.44 millionN/A-14.13Earnings Announcement
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.20-1.9%$190.73 millionN/A-8.78Upcoming Earnings
Genfit logo
GNFT
Genfit
1.3$4.87-0.6%$188.08 million$45.88 million-2.47Gap Down
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$5.34-22.1%$175.79 million$1.45 million-1.87Increase in Short Interest
Analyst Revision
News Coverage
Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.41-3.0%$171.37 million$2.33 million0.00Upcoming Earnings
Gap Down
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.43-1.1%$160.05 millionN/A0.00Upcoming Earnings
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.79-2.1%$159.42 millionN/A-1.99Upcoming Earnings
Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.94-1.0%$157.33 million$20,000.000.00
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.37-3.1%$156.69 million$32.12 million-87.46Upcoming Earnings
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.40-1.1%$154.73 millionN/A-2.94Earnings Announcement
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$14.46-1.2%$149.71 millionN/A0.00
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.69-0.0%$143.96 millionN/A-1.86
Dyadic International logo
DYAI
Dyadic International
1.3$5.14-3.7%$136.04 million$1.68 million-15.12
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.68-0.0%$128.14 million$23.05 million-2.08
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.9$8.14-1.0%$127.24 million$3 million-2.62Increase in Short Interest
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.57-1.7%$125.38 millionN/A-3.40
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.38-2.9%$110.98 million$20.92 million-1.37Analyst Downgrade
Analyst Revision
AIM
AIM ImmunoTech
1.7$2.04-0.5%$83.41 million$140,000.000.00Upcoming Earnings
Organovo logo
ONVO
Organovo
0.7$10.27-4.0%$76.01 million$2.20 million0.00Decrease in Short Interest
Gap Up
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$10.40-3.2%$73.84 millionN/A0.00
BBI
Brickell Biotech
1.1$1.16-0.9%$62.61 million$7.92 million-0.48Upcoming Earnings
Gap Up
WINT
Windtree Therapeutics
2.0$4.04-9.2%$62.10 million$200,000.00-1.68News Coverage
Gap Down
GENE
Genetic Technologies
0.4$4.22-6.6%$59.18 million$10,000.000.00
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.53-3.9%$56.29 millionN/A-1.21Upcoming Earnings
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.96-0.6%$56.22 millionN/A0.00
BioCardia logo
BCDA
BioCardia
2.0$3.33-5.1%$43.50 million$710,000.00-1.72Analyst Revision
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.39-3.9%$42.98 million$420,000.00-1.65Gap Down
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$5.12-2.0%$41.73 million$192.41 million0.93Earnings Announcement
Increase in Short Interest
BVXV
BiondVax Pharmaceuticals
0.5$3.64-0.5%$41.10 millionN/A-1.21Gap Up
SNCA
Seneca Biopharma
0.6$1.23-3.3%$20.58 million$10,000.000.00Increase in Short Interest
Gap Down
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.77-1.1%$19.99 million$3.61 million-0.37
ENTX
Entera Bio
0.5$1.50-6.0%$16.12 million$240,000.00-2.21Gap Up
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.